Real-World Safety Profile of Ibrutinib in Chronic Lymphocytic Leukemia: A Focus on Adverse Events, Discontinuations, and Effectiveness Outcomes
Annals of Pharmacotherapy · 2026
DOI: 10.1177/10600280251334133 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Pharmacotherapy, 2026. Verfasst von Alejandro Martínez Pradeda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Service, Complexo Hospitalario Universitario de A Coruña, Universidade da Coruña, Grupo de Investigación en Farmacia Hospitalaria Instituto …. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Piperidines, Adenine, Antineoplastic Agents. Die Arbeit nennt 30 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Ibrutinib has transformed chronic lymphocytic leukemia (CLL) treatment, offering significant survival benefits in clinical trials. However, real-world evidence is essential to understand its safety and efficacy in broader patient populations.
Objective
To evaluate ibrutinib safety and effectiveness in a real-world cohort of CLL patients focusing on dose reductions, adverse events, and survival outcomes.
Methods
This single-center, retrospective, observational study of CLL patients treated with ibrutinib was conducted between January 2015 and June 2023. Data were retrieved from the IANUS electronic medical records including patient demographics, treatment indications, genetic markers, comorbidities, adverse events, and dose changes.
Results
This study involved 90 patients with a median age of 71.5 years. Most patients presented with advanced-stage disease (BINET C: 46%, RAI IV: 25%). Cardiovascular comorbidities were common (70%) and 11% had prior bleeding events. Severe adverse events (grade 3-4) occurred in most patients (60%) with infections (33.3%) and neutropenia (14.4%) being the most common. Dose reductions were required in 11.1% of patients mainly due to hematological toxicities and 22% discontinued treatment due to adverse events. However, dose reductions and severe adverse events did not significantly affect overall survival or progression-free survival. The overall response rate was 82.2%, with 42.2% achieving complete remission. Multivariate analysis identified age and comorbidities as significant predictors of severe adverse events but not survival outcomes. Conclusion and Relevance: Ibrutinib remains an effective treatment for lymphocytic leukemia, even in patients with comorbidities and high-risk genetic characteristics. The study supports dose adjustment as a viable strategy for managing toxicities without compromising efficacy. These findings highlight the need for personalized care and proactive management of adverse events in clinical practice, particularly in elderly patients or those with multiple comorbidities. Long-term clinical studies are essential to refine treatment strategies and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Service, Complexo Hospitalario Universitario de A Coruña, Universidade da Coruña, Grupo de Investigación en Farmacia Hospitalaria Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain.
- Pharmacy Service, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain.
- Hematology and Hemostasia Service, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain.
- Clinical Epidemiology and Biostatistics Unit, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
- Hematology and Hemostasia Service, Complexo Hospitalario Universitario de A Coruña, Universidade da Coruña, Instituto de Investigación Biomédica de A Coruña, A Coruña, Spain.
ORCID-Profile: Alejandro Martínez Pradeda, Pablo Feijoo Vilanova, Luis Margusino-Framiñán
Zitieren
APA
Martínez Pradeda, A., Feijoo Vilanova, P., Fernández Gabriel, E., Giménez Arufe, V., Vale López, A. M., Suanzes-Hernández, J., Margusino-Framiñán, L., & Noriega Concepción, V. (2026). Real-World Safety Profile of Ibrutinib in Chronic Lymphocytic Leukemia: A Focus on Adverse Events, Discontinuations, and Effectiveness Outcomes. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251334133
Vancouver
Martínez Pradeda A, Feijoo Vilanova P, Fernández Gabriel E, Giménez Arufe V, Vale López AM, Suanzes-Hernández J, et al. Real-World Safety Profile of Ibrutinib in Chronic Lymphocytic Leukemia: A Focus on Adverse Events, Discontinuations, and Effectiveness Outcomes. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280251334133
BibTeX
@article{MartnezPradeda2026,
author = {Martínez Pradeda, Alejandro and Feijoo Vilanova, Pablo and Fernández Gabriel, Elena and Giménez Arufe, Víctor and Vale López, Ana María and Suanzes-Hernández, Jorge and Margusino-Framiñán, Luis and Noriega Concepción, Víctor},
title = {Real-World Safety Profile of Ibrutinib in Chronic Lymphocytic Leukemia: A Focus on Adverse Events, Discontinuations, and Effectiveness Outcomes},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280251334133}
}
EUVIMED